B. VanLunen

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

Paul Emery, Clifton O. Bingham, Gerd R Burmester et al. · Annals of the Rheumatic Diseases · 2016 · 100 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX

Ernest Choy, Frank McKenna, Jiří Vencovský et al. · Lara D. Veeken · 2012 · 82 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension

Edward Keystone, Robert Landewé, Ronald van Vollenhoven et al. · Annals of the Rheumatic Diseases · 2013 · 54 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

Michael E. Weinblatt, Clifton O. Bingham, Gerd‐Rüdiger Burmester et al. · Arthritis & Rheumatology · 2017 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

Irene van der Horst‐Bruinsma, Rianne van Bentum, Frank D. Verbraak et al. · RMD Open · 2020 · 36 citations · Full text

Medicine, Immunology, Pharmacotherapy +17